NASDAQ · Financial Statements

Biofrontera Inc. (BFRI) Revenue, Earnings & Financial Statements

$0.59 NASDAQ: BFRI Market Cap $8.81M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Biofrontera Inc. most recently reported annual revenue of $42.0M, a net loss of $11.0M. Revenue grew at an average annual rate of 17.2% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Biofrontera Inc.: Revenue rose from $26.0M in 2019 to $42.0M in 2025, a change of +61.5% over 6 years; net profit was positive in 0 of 7 reported years; operating margin moved from -57.0% to -21.9%, a shift of +35.1 percentage points; the most recent year shows a net loss of $11.0M.

Income Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Revenue$26.0M$19.0M$24.0M$29.0M$34.0M$37.0M$42.0M
Operating Expenses$41.0M$28.0M$49.0M$47.0M$57.0M$55.0M$51.0M
Operating Profit−$15.0M−$10.0M−$25.0M−$19.0M−$23.0M−$17.0M−$9.0M
Operating Margin-57.0%-51.0%-104.6%-64.8%-66.6%-46.1%-21.9%
Other Income$4.0M−$1.0M−$12.0M$18.0M$3.0M−$1.0M−$1.0M
Interest$2.0M$3.0M$0$0$1.0M$2.0M$0
Depreciation$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M
Profit Before Tax−$11.0M−$11.0M−$38.0M−$1.0M−$20.0M−$18.0M−$11.0M
Tax rate (%)-0.3%-0.6%-0.1%-5.3%-0.1%-0.1%-0.2%
Net Profit−$11.0M−$11.0M−$38.0M−$1.0M−$20.0M−$18.0M−$11.0M
EPS−$18.09−$18.94−$44.10−$0.61−$13.02−$3.22−$0.90

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$11.0M$8.0M$8.0M$9.0M$13.0M$9.0M$9.0M$7.0M$17.0M$10.0M$12.0M$9.0M
Operating Expenses$14.0M$13.0M$13.0M$14.0M$14.0M$13.0M$14.0M$13.0M$10.0M$14.0M$13.0M$16.0M
Operating Profit−$4.0M−$5.0M−$5.0M−$5.0M−$2.0M−$5.0M−$5.0M−$6.0M$7.0M−$4.0M−$1.0M−$6.0M
Operating Margin-36.5%-69.2%-64.7%-55.0%-13.6%-53.0%-56.3%-89.8%39.5%-42.8%-4.4%-71.6%
Interest$0$1.0M$1.0M$0$0$0$0$0$0$0$0$0
Profit Before Tax$4.0M−$10.0M$0−$6.0M−$1.0M−$4.0M−$5.0M−$7.0M$6.0M−$5.0M−$1.0M−$6.0M
Tax rate (%)-0.2%-0.0%-8.4%-0.1%0.2%0.0%-0.4%-0.1%0.0%0.0%-4.0%-0.1%
Net Profit$4.0M−$10.0M$0−$6.0M−$1.0M−$4.0M−$5.0M−$7.0M$6.0M−$5.0M−$1.0M−$6.0M
EPS$1.65−$2.88−$0.05−$0.98−$0.19−$0.76−$0.57−$0.62$0.48−$0.41−$0.05−$0.42

Over the 7 years reported for Biofrontera Inc., borrowings decreased from $38.0M in 2019 to $6.0M in 2025, cash stood at $6.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 1.50 times.

Balance Sheet — 7 Years (USD millions)

Metric2019202020212022202320242025
Total Assets$29.0M$24.0M$53.0M$51.0M$28.0M$22.0M$29.0M
Current Assets$23.0M$20.0M$46.0M$43.0M$23.0M$21.0M$18.0M
Cash$7.0M$8.0M$25.0M$17.0M$1.0M$6.0M$6.0M
Inventory$10.0M$7.0M$4.0M$7.0M$11.0M$7.0M$1.0M
Receivables$5.0M$3.0M$4.0M$7.0M$5.0M$5.0M$7.0M
Fixed Assets$1.0M$0$0$2.0M$2.0M$1.0M$4.0M
Capital Work in Progress$0$0$0$0$0$0$0
Investments$0$0$3.0M$11.0M$0$0$0
Other Assets$0$0$0$0$0$0$0
Total Liabilities$59.0M$18.0M$42.0M$27.0M$23.0M$18.0M$18.0M
Current Liabilities$12.0M$4.0M$14.0M$21.0M$18.0M$12.0M$12.0M
Borrowings$38.0M$0$0$1.0M$5.0M$5.0M$6.0M
Other Liabilities$21.0M$18.0M$42.0M$26.0M$18.0M$13.0M$12.0M
Equity$0$0$0$0$0$0$0
Reserves−$30.0M$6.0M$11.0M$24.0M$5.0M$4.0M$10.0M

For Biofrontera Inc., operating cash flow was positive in 0 of 7 reported years; free cash flow in the latest year was negative at $13.0M; free cash flow was positive in 0 of 7 years; financing activities used $11.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Operating Cash Flow−$38.0M−$12.0M−$27.0M−$16.0M−$25.0M−$10.0M−$13.0M
Investing Cash Flow$25.0M$0$0−$5.0M$1.0M$0$3.0M
Financing Cash Flow$3.0M$4.0M$13.0M$5.0M$0$7.0M−$11.0M
Net Cash Flow$4.0M$1.0M$16.0M−$7.0M−$16.0M$5.0M$0
Free Cash Flow−$38.0M−$12.0M−$27.0M−$16.0M−$25.0M−$10.0M−$13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-2.76
FCF Yield-53.37%
Quick Ratio0.66
Interest Coverage-18.41
Return 1Y-21.35%
Return 3Y-82.46%
Return 5Y-98.61%

Biofrontera Inc. (BFRI) financials — frequently asked questions

What is Biofrontera Inc.'s annual revenue?

Biofrontera Inc. (BFRI) reported annual revenue of $42.0M in its most recent fiscal year.

What is Biofrontera Inc.'s net profit?

Biofrontera Inc. (BFRI) reported a net loss of $11.0M in its most recent fiscal year.

What is BFRI EV/EBITDA?

Biofrontera Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -2.76. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Medical - Pharmaceuticals stocks

RPRX revenue $2.4BCORT revenue $761.0MLQDA revenue $158.0MPBH revenue $1.1BQUIT financialsHITI revenue $594.0METRA stockTRXB stockAll Medical - Pharmaceuticals stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
BFRI Overview BFRI Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.